Clinical predictors of flare and drug-free remission in rheumatoid arthritis: preliminary results from the prospective BIO-FLARE experimental medicine study

Rheumatoid Arthritis

Stepwise dose reduction and discontinuation of bDMARD in rheumatoid arthritis: a prospective cohort study of flare-free population, flares, and predictive markers

Arthritis Res Ther

Nozaki Y, Kishimoto K, Tomita D, Itami T, Ashida C, Shiga T, Yamazawa H, Ishimura K, Morimoto Y, Fukuda R, Kinoshita K

doi: 10.1186/s13075-025-03672-y

Rheumatoid Arthritis

Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study

Arthritis Res Ther

Picchianti Diamanti A, Paci V, Luchetti Gentiloni MM, Salemi S, Sesti G, Bellofatto IA, Baldi C, Falsetti P, Chimenti MS, D'Antonio A, Crepaldi G, Zabotti A, Giovannini I, Canzoni M, Fiore D, Sebastiani GD, Scirocco C, Perricone C, Laganà B, Iagnocco A

doi: 10.1186/s13075-025-03671-z

Rheumatoid Arthritis

Clinical and Ultrasound Remission in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A Real-World Study

J Clin Med

Lasa-Teja C, Fernández-Cabero JJ, Sánchez-Bilbao L, Loricera J, González-Mazón I, Álvarez-Reguera C, Herrero-Morant A, Corrales-Martínez A, Portilla-González V, Martín-Varillas JL, Pérez-Garrido L, Santos-Gómez M, López-Hoyos M, Blanco R

doi: 10.3390/jcm15010278

Rheumatoid Arthritis

Towards the development of a definition of independence for individuals diagnosed with rheumatoid arthritis in remission: an 'OMERACT remission in rheumatoid arthritis patient perspective' special interest group report

Semin Arthritis Rheum

Gazel U, Barnes E, Jones B, Terrett A, Voshaar M, Hoogland W, March L, Beaton D, Khoo T, Chin A, Shea B, Tugwell P, Proudman S, Flurey CA

doi: 10.1016/j.semarthrit.2026.152948

Rheumatoid Arthritis

Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies

RMD Open

Taylor PC, Kavanaugh A, Bessette L, Fautrel B, Takeuchi T, Garrison A, Gao T, Lippe R, Caballero D, Phillips C, Mease PJ

doi: 10.1136/rmdopen-2025-005867

Rheumatoid Arthritis

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug

Arthritis Care Res (Hoboken)

Xie F, Beukelman T, McCormick NP, Curtis JR

doi: 10.1002/acr.80010

Further Publications Rheumatology

Clinical impact of multiparametric contrast-enhanced dual-energy computed tomography in arthritis imaging - a prospective single-center study

Arthritis Rheumatol

Ulas ST, Mews J, Ohrndorf S, Biesen R, Ziegeler K, Wiebe E, Proft F, Schneider U, Poddubnyy D, Diekhoff T

doi: 10.1002/art.43270

Rheumatoid Arthritis

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors

Semin Arthritis Rheum

Raskin N, Hiligsmann M, Rebutoc AR, Bansback N, Boonen A, Buchbinder R, Falahee M, Fraenkel L, Marshall DA, Maxwell L, Nieuwlaat R, Proulx L, Saadat P, Shea B, Tugwell P, Wiercioch W, Beaton D, Richards P, Schünemann H, Guillemin F, Hazlewood GS

doi: 10.1016/j.semarthrit.2025.152769

Rheumatoid Arthritis

Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

Arthritis Rheumatol

Liu J, Li Y, Fu K, Wu C, Schafer P, Connolly SE, Catlett IM, Maldonado MA, Wong R, Emery P, Tanaka Y, Bykerk VP, Bingham CO, Huizinga TWJ, Fleischmann R

doi: 10.1002/art.70106

Related content

Stepwise dose reduction and discontinuation of bDMARD in rheumatoid arthritis: a prospective cohort study of flare-free population, flares, and predictive markers

Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study

Clinical and Ultrasound Remission in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A Real-World Study

Towards the development of a definition of independence for individuals diagnosed with rheumatoid arthritis in remission: an 'OMERACT remission in rheumatoid arthritis patient perspective' special interest group report

Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug

Clinical impact of multiparametric contrast-enhanced dual-energy computed tomography in arthritis imaging - a prospective single-center study

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors

Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis